Postmastectomy radiation: Then and now

ONCOLOGY

Volumn 11, Issue 2, 1997, Pages 213-239

  Fowble, Barbara ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; FEMALE; HUMAN; MASTECTOMY; MORTALITY; RADIATION; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; META-ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 0030993786     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Hellman S: Karnofsky Memorial Lecture: Natural history of small breast cancer J Clin Oncol 12:2229-2234, 1994.
2. Hellman S, Weichselbaum R: Radiation oncology and the new biology. Cancer J Sci Am 1:174-179, 1995.
3. Fowble B: The relationship between local relapse and distant metastases revisted. Int J Radiat Oncol Biol Phys 30:237-239, 1994.
4. Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 13:2689-2878,1995.
5. Aberizk WJ, Silver B, Henderson IC, et al: The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58:1214-1218, 1986.
6. Schwaibold F, Fowble EL, Solin LJ, et al: The results of radiation therapy for isolated local-regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 11:299-310, 1991.
7. Bedwinek JM, Lee J, Fineberg B, el al. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 47:2232-2235, 1981.
8. Magno L, Bigrardi M, Micheletti E, et al: Analysis of prognostic factors in patients with isolated chest wall recurrence of breast cancer. Cancer 60:240-244, 1987.
9. Janjan NA, McNeese MD, Buzdar AU, et al: Management of locoregional recurrence of breast cancer. Cancer 58:1552-1556, 1986.
10. Halverson KJ, Perez CA, Kuske RR, et al: Isolated local-regional recurrence of breast cancer following mastectomy: Radiotherapeutic management. Int J Radiat Oncol Biol Phys 19:851-858, 1990.
11. Fowble B, Schwaibold F: Local-regional recurrence following definitive treatment for operable breast cancer, in Fowble B, Goodman RL, Glick JH, et al (eds): Breast Cancer Treatment. A Comprehensive Guide to Management, pp 373-403. St. Louis, Mosby, 1991.
12. Easson EC: Post operative radiotherapy in breast cancer, in Forrest APM and Kunkler PB (eds): Prognostic Factors in Breast Cancer, pp 118-135. Edinburgh, E&S Livingstone, 1968.
13. Palmer MK, Ribeiro GO: Thirty-four year follow-up of patients with breast cancer in clinical trial of postoperative radiotherapy. Br Med J 291:1088-1091, 1985
14. Fisher B, Slack NH, Cavanaugh PJ, et al: Post-operative radiotherapy in the treatment of breast cancer: Results of the NSABP clinical trial. Ann Surg 172-711-732, 1970.
15. Rutqvist LE, Cedermark B, Glas U, et al: Radiotherapy, chemotherapy and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials. Int J Radiat Oncol Biol Phys 15:629-639, 1989.
16. Wallgren A, Arner O, Bergstrom J, et al: Radiation therapy in operable breast cancer Results from the Stockholm trial on adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 12:533-537, 1986.
17. Auquier A, Rutquist LE, Host H, et al: Post-mastectomy megavoltage radiotherapy: The Oslo and Stockholm trials. Eur J Cancer 28:433-437, 1992.
18. Rutqvist LE, Pettersson D, Johansson H: Adjuvant radiation therapy versus surgery alone in operable breast cancer: Long-term follow-up at a randomized clinical trial. Radiother Oncol 26:104-110, 1993.
19. Host H, Brennhoud IO, Loeb M: Postoperative radiotherapy in breast cancer: Longterm results from the Oslo study. Int J Radiat Oncol Biol Phys 12:727-732, 1986.
20. Jones JM, Ribeiro GG: Morality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. Clin Radiol 40:204-208, 1989.
21. Berstock DA, Houghton J, Haybittle J, et al: The role of radiotherapy following total mastectomy for patients with early breast cancer. World J Surg 9:667-670, 1985.
22. Cancer Research Campaign Working Party: Cancer Research Campaign (King's/Cambridge) trial for early breast cancer: A detailed update at the tenth year. Lancet 12:55-60, 1980.
23. Forrest APM, Roberts MM, Cant ELM, et al: Simple mastectomy and pectoral node biopsy: The Cardiff-St. Mary's Trial. World J Surg 1:320-323, 1977.
24. Lythgoe JP, Palmer MK: Manchester Regional Breast Study: 5- and 10- year results. Br J Surg 69:693-696, 1982.
25. Turnbull AR, Chant ADB, Buchanan RB, et al: Treatment of early breast cancer. Lancet ii:7-9, 1978.
26. Fisher B, Redmond C, Fisher ER, et al: Ten year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985.
27. Brinkley D, Haybittle JL, Houghton J: The Cancer Reserach Campaign (King's/Cambridge) trial for early breast cancer: An analysis of the radiotherapy data. Br J Radiol 57:309-316, 1984.
28. Lythgoe JP, Leek I, Swindell R: Manchester regional breast study: Preliminary results. Lancer 1:744-747, 1978.
29. Fowble B. The role of postmastectomy adjuvant radiotherapy for operable breast cancer, in Fowble B, Goodman RL, Click JH, et al (eds): Breast Cancer Treatment, A Comprehensive Guide to Management, pp 289-309. St. Louis, Mosby, 1991
30. Cuzick J, Stewart H, Peto H, et al: Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 71:15-29, 1987.
31. Haybittle JL, Brinkley D, Houghton J, et al: Postoperative radiotherapy and late mortality: Evidence from the Cancer Research Campaign trial for early breast cancer. Br Med J 298:1611-1614, 1989.
32. Gyenes G, Pomander T, Carlens P, et al: Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy Int J Radiat Oncol Biol Phys 28:1235-1241, 1994.
33. Rutqvist LE, Lat I, Fornander MD. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22:887-896, 1992.
34. Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994.
35. Donegan WL, Perez-Mesa CM, Watson FR: A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 122:529-540, 1966.
36. Dao TL, Nemoto T: The clinical significance of skin recurrence after radical mastectomy in women with cancer of the breast. Surg Gynecol Obstet 117:447-453, 1963.
37. Baker RR, Montague AC, Childs JN: A comparison of modified radical mastectomy to radical mastectomy in the treatment of operable breast cancer. Ann Surg 189:553-559, 1979.
38. Maddox WA, Carpenter JT, Laws HT, et al: A randomized prospective trial of radical (Halsted) mastectomy versus modified radical mastectomy in 311 breast cancer patients. Ann Surg 198:207-212, 1983.
39. Rosenman J, Bernard S, Kober C. et al: Local recurrences in patients with breast cancer treated at the North Carolina Memorial Hospital. Cancer 57-.1421-1425, 1986.
40. Ahlborn TN, Gump FE, Bodain C, et al: Tumor to fascia margin as a factor in local recurrence after modified radical mastectomy. Surg Gynecol Obstet 166:523-526, 1988.
41. Haagensen CD: My personal technique for the Halsted radical mastectomy, in Haagensen CD (ed): Diseases of the Breast, 3rd ed. pp 872-902. Philadelphia, WB Saunders, 1986.
42. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Cancer 41:1170-1178, 1978.
43. Overgaard M, Christensen JJ, Johansen H, et al: Post-mastectomy irradiation in high risk breast cancer patients: Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncol 27:707-714, 1988.
44. Hopton DS, Thorogood J, Clayden AD, et al: Histologic grading of breast cancer: Significance of grade on recurrence and mortality. Eur J Surg Oncol 15:25-31, 1989.
45. Deck KB, Kern WH: Local recurrence of breast cancer Arch Surg 111:323-325, 1976.
46. Lee YN. Breast carcinoma: Pattern of recurrence and metastasis after mastectomy. Am J Clin Oncol 7:443, 1984.
47. Crowe JP, Gordon NH, Antunez AR, et al: Local-regional breast cancer recurrence following mastectomy. Arch Surg 126:429-432, 1991
48. Lewis D, Rienhoff WFJ: A study of the results of operations for the cure of cancer of the breast, performed at Johns Hopkins Hospital from 1889 to 1931. Ann Surg 95:336-344, 1932.
49. Matthews RH, McNeese M, Montague ED, et al: Prognostic implications of age in breast cancer patients treated with tumorectomy and irradiation or with mastectomy. Int J Radiat Oncol Biol Phys 14:659-663, 1988.
50. Campbell F, Blarney R, Elston C, et al: Estrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer44:456-461, 1981.
51. Sykes HF, Sim DA, Wong CJ, et al: Local-regional recurrences in breast cancer after mastectomy and Adriamycin-based adjuvant chemotherapy: Evaluation of the role of postoperative radiotherapy. Int J Radiat Oncol Biol Phys 16:641, 1989.
52. Donegan WL. Local and regional recurrence, in Donegan WL and Spratt JS (eds): Cancer of the Breast, pp 648-663. Philadelphia, WB Saunders, 1988.
53. Williams MR, Hinton CP, Todd JH, et al: The prediction of local or regional recurrence after simple mastectomy for operable breast cancer. Br J Surg 72:721, 1985.
54. Fowble B, Gray R, Gilchrist K, et al: Identification of a subgroup of patients with breast cancer and histologically positive nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6:1107-1117, 1988.
55. Mentzer SJ, Osteen RT, Wilson RE: Local recurrence and the deep resection margin in carcinoma of the breast. Surg Gynecol Obstet 16:513, 1986.
56. Danoff BF, Cola LR, Cantor RI, et al: Locally recurrent breast carcinoma: The effect of adjuvant chemotherapy on prognosis. Radiology 147:849-952, 1983.
57. Pawlias KT, Dockerly MB, Ellis FH: Late locally recurrent carcinoma of the breast. Ann Surg 148:192-196, 1958.
58. Fisher B, Wolmark N. Bauer M, et al: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765-772, 1981.
59. Pierce LJ, Oberman HA, Strawderman MH, et al: Microscopic extracapsular extension in the axilla: Is this an indication for axillary radiotherapy? Int J Radiat Oncol Biol Phys 33:253-259, 1995
60. Donegan WL, Stine SB, Samter TG: Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 72-778-782, 1993.
61. Leonard C, Corkill M, Tompkin J, et al. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. J Clin Oncol 13:47-53, 1995
62. Perera F, Fisher BJ, Cooke A, et al: Locoregional recurrence and extranodal extension in patients receiving systemic therapy for axillary node positive breast cancer (abstract). Int J Radiat Oncol Biol Phys 27:265, 1993
63. Di Pietro S, Bertario L, Piva L: Prognosis and treatment of loco-regional breast cancer recurrences: Critical considerations on 120 cases. Tumori 66:331-336, 1980.
64. Shimkin MB, Lucia EL, Low-Beer VA, et al: Recurrent cancer of the breast: Analysis of frequency, distribution and mortality at the University of California Hospital, 1918 to 1947, inclusive. Cancer 7:29-34, 1954.
65. Montague ED: Conservative surgery and radiation therapy in the treatment of operable breast cancer. Cancer 53:700, 1984.
66. Early Breast Cancer Trialists Collaborative Group: Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. N Engl J Med 333:1444-1455, 1995.
67. Rao AF, Murthy AK, Hendrickson FR, et al: Analysis of risk factors for loco-regional failure in stage II breast carcinoma treated with mastectomy and adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 11:151, 1985.
68. Stefanik D, Goldberg R, Bryne P, et al: Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 3:660-665, 1985.
69. Pisanky TM, Ingle JN, Schaid DJ, et al: Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer: Impact on clinical, histopathologic and flow cytometric factors. Cancer 72:1247-1260, 1993
70. Morrison JM, Howell A, Kelly KA, et al: West Midlands Onocology Association trials of adjuvant chemotherapy in operable breast cancer: Results after a median follow-up of 7 years: I. Patients with involved axillary nodes. Br J Cancer 60:911-918, 1989.
71. Bonadonna G, Valagussa P, Tancini G, et al: Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1:45 49, 1986.
72. Richards MA. O'Reilly SM, Howell A, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with axillary node-positive breast cancer: An updae of the Guy's/Manchester trial. J Clin Oncol 8:2032-2039, 1990.
73. Misset JL, dipalma M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16 year median follow-up duration. J Clin Oncol 14:1136-1145, 1996.
74. Fisher B, Fisher ER, Redmond C: Ten-year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929-935, 1986.
75. Rubens RD, Knight RK, Fentiman IS, et al: Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet i:839-843, 1983.
76. Goldhirsch A, Gelber R: Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies. NCI Monogr 1:55-70, 1986.
77. Ingle JN, Everson LK, Wieand HS, et al: Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 6:1388-1396, 1988
78. Ludwig Breast Cancer Group: Combination adjuvant chemotherapy for node-positive breast cancer: Inadequacy of a single perioperative cycle. N Engl J Med 319:677-683, 1988.
79. Fisher B. Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage 11 breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989
80. Fisher B, Brown A, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval remduction therapy compared with 6 months of cydophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990.
81. Budd GT, Green S, O'Bryan RM, et al: Short course FAC-M versus 1 year of CMFVP in node-positive hormone receptor-negative breast cancer An intergroup study. J Clin Oncol 13:831-839, 1995.
82. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991.
83. Buzzoni R, Bonadonna G, Valagusso P, et al. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991.
84. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results JAMA 273:542-547, 1995.
85. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen m premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10:1848-1856, 1992.
86. Gianni AM, Siena S, Bregni M, et al: 5-year results of high-dose sequential adjuvant chemotherapy in breast cancer with > 10 positive nodes. Proc Am Soc Clin Oncol 14:90, 1995.
87. Dimitrov N, Anderson S, Fisher B, et al: Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22 (abstract). Proc Am Soc Clin Oncol 13:64, 1994.
88. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 330:1253-1259, 1994.
89. Peters WP, Berry D, Vredenburgh JJ, et al: Five year follow-up of high dose combination alkalating agents with ABMT as consolidation after standard-dose CAP for primary breast cancer involving > 10 axillary nodes (Duke/CALGB 8782) (abstract). Proc Am Soc Clin Oncol 14:317, 1995.
90. Marks LB, Halperin EC, Prosnitz LR, et al: Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patientswith > 10 positive axillary nodes. Int J Radiat Oncol Biol Phys 23:1021-1026, 1992.
91. Marks LB, Rosner GL, Prosnitz LR, et al: The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. Cancer 74:2964-2971, 1994.
92. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993.
93. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377-381, 1994.
94. Tennrall-Nittby L, Tengrup J, Landberg T: The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial. Acta Oncol 32:641-646, 1993.
95. Goldhirsch A, Gelber RD, Castiglione M: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses. J Clin Oncol 6:89-97, 1988.
96. Rutqvist L, Cedermark B, Fornander T, et al: The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 17:1474-1484, 1989.
97. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at six years by Nolvadex Adjuvant Trial Organization. Lancet 1:836-840, 1985.
98. Aitken RJ, Gaze MN, Rodger A, et al: Arm morbidity within a trial of mastectomy and either nodal sample with selective radiotherapy or axillary clearance. Br J Surg 76:568-571, 1989.
99. Kaufmann M, Jonat W, Abel U, et al: Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/ tamoxifen andCMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 11:454-460, 1993
100. Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group Study. J Clin Oncol 12:2078-2085, 1994.
101. Rutqvist LE, Cedermark B, Glas U, et al: Randomized trial of adjuvant tamoxifen combined with post-operative radiotherapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 66:89-96, 1990.
102. Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy vs tamoxifen vs chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer 28:673-680, 1992.
103. Fisher B, Redmond C, Legault-Poisson S, et al: Post-operative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of postive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Breast and Bowel Project B16. J Clin Oncol 8:1005-1018, 1990.
104. Rose C, Anderson J, Axelsson M, et al: A randomized DBCG trial of adjuvant tamoxifen and radiotherapy vs. tam alone vs tarn and CMF in postmenopausal breast cancer patients with high risk of recurrence (abstract). Proc Am Soc Clin Oncol 11:58, 1992.
105. Overgaard M, Christensen JJ, Johansen H, el al: Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (BBCG 82) trial. Int J Radiat Oncol Biol Phys 19:1121-1124, 1990.
106. Pritchard KI, Zee B, Paul N, et al: CMF added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer. Negative results from a randomized clinical trial (abstract). Proc Am Soc Clin Oncol 13:65, 1994.
107. Pritchard KJ, Paterson AHG, Fine S, et al: A randomized trial of CMF chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node positive-estrogen and/or progesterone receptor-positive breast cancer (abstract). Proc Am Soc Clin Oncol 11: 60, 1992.
108. McArdle CS, Crawford D, Dykes EH, et al: Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 73:264-266, 1986.
109. Smith DC, Crawford D. Dykes EH, et al. Adjuvant radiotherapy and chemotherapy in breast cancer, in Jones SE and Salmon SE (eds): Adjuvant Therapy of Cancer IV, pp 283-289. Orlando, Grune &Stratton, 1984.
110. Grohn P, Heinonen E, Klefstrom P, et al: Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 54:670-674, 1984.
111. Klefstrom P, Grohn P, Heinonen E, et al: Adjuvant post-operative radiotherapy, chemotherapy and immunotherapy in stage III breast cancer. Cancer 60:936-942, 1987.
112. Olson JE, Neuberg D, Pandya K, et al: The management of resectable stage III breast cancer: The Easter Cooperative Oncology Group Trial (abstract). Proc Am Soc Clin Oncol 8:23, 1989.
113. Spangenberg JP, Nel CJC, Anderson ID, et al: A prospective study of the treatment of stage III breast cancer. S Afr J Surg 24:57, 1986.
114. Allen H, Brooks R, Jones SE, et al: Adjuvant treatment for stage II (node-positive) breast cancer with Adriamycin-cyclophosphamide (AC) and radiotherapy (XRT), in Salmon SE and Jones SE (eds): Adjuvant Therapy for Cancer III, pp 453-562. New York, Grune & Stratton, 1981.
115. Griem K, Henderson IC, Gelman R, et al: Post-operative radiotherapy after adjuvant chemotherapy in breast cancer patients: Results of a randomized trial. J Clin Oncol 5:1546, 1987.
116. Ragaz J, Jackson SM, Plenderleith IH, et al: Can adjuvant radiotherapy improve the overall survival of breast cancer patients in the presence of adjuvant chemotherapy? 10-year analysis of the British Columbia randomized trial (abstract) Proc Am Soc Clin Oncol 12:60, 1993.
117. Velez-Garcia E, Carpenter IT Jr., Moore M, et al: Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes' A Southeastern Cancer Study Group (SEG) trial. Eur J Cancer 28A: 1833-1837, 1992.
118. Ragaz J, Jackson S, Le N, et al. Can adjuvant locoregional therapy reduce systemic recurrences in stage I-II breast cancer patients? Recurrence analysis of the British Columbia randomized trial (abstract). Proc Am Soc Clin Oncol 15:121, 1996.
119. Dombernowsky P, Zedeler K, Hansen M, et al. Randomized trial of adjuvant CMF and radiotherapy vs. CMF alone vs. CMF and tamoxifen in pre and menopausal stage 11 breast cancer (abstract). Proc Am Soc Clin Oncol 11:54, 1992.
120. Dombernowsky P, Hansen PS, Mouridsen HT, et al: Randomized trial of adjuvant CMF and radiotherapy vs. CMF alone vs. CMF and tamoxifen in pre and menopausal stage II breast cancer (abstract). Eur J Cancer 30A:S28, 1994.
121. Ahmann DL, O'Fallon JR, Scanlon PW, et al: A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 5:371-381, 1982.
122. Martinez A, Ahmann D, O'Fallon J, et al. An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer (abstract). Int J Radiat Oncol Biol Phys 10: 150, 1985.
123. Suit HD, Westgate SJ. Impact of improved local control on survival. Int J Radiat Oncol Biol Phys 12:453-458, 1986.
124. Rose C, Hansen M, Dombernowsky P, et al: A randomized DBCG trial of adjuvant tamoxifen and radiotherapy vs. tamoxifen alone vs. tamoxifen and CMF in postmenopausal breast cancer patients with high risk of recurrence (abstract). Eur J Cancer 30 A: S28, 1994.
125. Overgaard M, Hansen SR, Engelholm S, et al: Postmastectomy radiotherapy and adjuvant systemic treatment in high-risk breast cancer patients. Eur J Cancer 30A:S28, 1994.
126. Mouridsen HT, Rose C, Overgaard M, et al: Adjuvant treatment of postmenopausal patients with high risk primary breast cancer: Results from the Danish adjuvant trials DBCG 77C and DBCG 82C. Acta Oncol 27:699-705, 1988.
127. Fowble B, Glick J, Goodman R: Radiotherapy for the prevention of local-regional recurrence in high risk patients post mastectomy receiving adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 15:627-631, 1988.
128. Uematsn M, Bernstein RA, Recht A, et al: Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast cancer. Int J Radiat Oncol Biol Phys 25:765-770, 1993.
129. Ung O, Langlands AO, Barraclough B, et al: Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J Clin Oncol 13:435-443, 1995.
130. Buzdar AU, Kau S-W, Hertobagyi GM, et al: Clinical course of patients with breast cancer with 10 or more positive nodes who were treated with doxorubicin-contaimng adjuvant therapy. Cancer 69:448-452, 1992.
131. Fowble B, Yeh I-T, Schultz DJ, et al: The role of mastectomy in patients with stage I-II breast cancer presenting with gross multifocal or multicentric disease or diffuse microcalcifications. Int J Radiat Oncol Biol Phys 27:567-573, 1993.
132. Halverson KJ, Taylor ME, Perez CA, et al: Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 26:593-599, 1993.
133. Buchholz TA, Austin-Seymour MM, Moe RE, et al: Effect of delay in radiation in the com- bined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys 26:23-35, 1993.
134. Buzdar AU, Kau SW, Smith TL, et al: The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. Cancer 11:3680-3684, 1993.
135. Klefstrom P, Nuortio L, Taskinen E: Postoperative radiation therapy and adjuvant chemoimmunotherapy in breast cancer Aspects of timing and immune competence. Acta Radiol 25:161-166, 1986.
136. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 yrs. of follow-up. N Eng J Med 322:901-906, 1995.
137. Lara Jimenez P, Garcia Puche J, Pedraza V: Adjuvant combined modality treatment in high-risk breast cancer patients: Ten-year results. A293 (abstract). 5th EORTC Breast Cancer Working Conference, Leuven, Belgium, 1991.
138. Brufman G, Sulkes A: Effect of timing of onset of chemotherapy on relapse-free survival in stage II breast cancer (abstract). Proc Am Soc Clin Oncol 5:62, 1986.
139. Shapiro CL, Recht A: Late effects of adjuvant therapy for breast cancer. J Natl Cancer Inst Monograph 16:101-112, 1994.
140. Abrams JS, Phillips PH, Friedman MA: Meeting highlights: A reappraisal of research results for the local treatment of early stage breast cancer. J Natl Cancer Inst 87:1837-1845, 1995.
141. Werner RS, McCormick B, Petrek J, et al: Arm edema in conservatively managed breast cancer: Obesity is a major predictive factor. Radiology 180:177-184, 1991.
142. Valagussa P, Zambetti M, Biasi S, et al: Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 5:209-216, 1994.
143. Harrigan P, Otis D, Recht A, et al: The effect of adjuvant radiation therapy on cardiac events in breast cancer patients treated with doxorubicin (abstract). Proc Am Soc Clin Oncol 14:102, 1995.
144. Hughes-Davies L, Sacks D, Rescigno J, et al: Serum cardiac troponin T levels during treatment of early stage breast cancer. J Clin Oncol 13:2582-2584, 1995.
145. Plunkett ME, Bernstein BA, Costello P, et al: Use of spiral CT in the assessment of cardiac structures for planning 3D volumetric radiation treatment of the breast (abstract). Radiology 189:355, 1993.
146. Janjan NA, Gillin MT, Prows J, et al: Dose to the cardiac vascular and conduction systems in primary breast irradiation. Med Dos 14:81-87, 1989.
147. Fuller SA, Haybittle JL, Smith REA, et al: Cardiac doses in postoperative breast irradiation. Radiother Oncol 25:19-24, 1992.
148. Danoff BF, Calvin JM, Cheng E, et al: The clinical application of CT scanning in the treatment of primary breast cancer, in Ames FC, Blumenschein GR, Montague ED (eds): Current Controversies in Breast Cancer. pp 391-397. Austin, University of Texas Press, 1984.
149. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
150. Allred DC, Clark GM, Tandon AK, et al: HER2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992.
151. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2-10, 1983
152. Muss HE, Thor AD, Berry DA, et al: C-erb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
153. Nordenskjold B, Stal O, Skoog L, et al: S-phase fraction and c-erb b-2 expression related to the survival benefit from adjuvant chemotherapy of breast cancer (abstract). Proc Am Soc Clin Oncol 13:67, 1994.
154. Jansson T, Inganas M, Sjogren S, et al: P53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy. A novel hypothesis based on clinical findings. J Clin Oncol 13:2745-2751, 1995.
155. Fisher B, Redmond C, and others for the National Surgical Adjuvant Breast and Bowel Project Systemic therapy in node-negative patients: Updated findings from NSABP clinical trials. J Natl Cancer Inst Monograph 11:105-115, 1992.
156. Mansour EG, Eudey L, Termey DC, et al: Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monograph 11:97-104, 1992.
157. Goldhirsch A, Castiglione M, Gelber RD (for the International Breast Cancer Study Group, formerly Ludwig Group): A single perioperative adjuvant chemotherapy course for node-negative breast cancer: Five-year results of trial V. J Natl Cancer Inst Monograph 11:89-96, 1992.
158. Zambetti M, Benadonno G, Valagusso P, et al: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. J Natl Cancer Inst Monograph 11:77-83, 1992.
159. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International (Ludwig) Breast Cancer Study Group trials I-IV: 15-year follow-up. Ann Oncol 5:717-724, 1994.
160. Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol 7:1229-1238, 1989.
161. Falkson HE, Gray RG, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus 4 cycles of CMFPT in postmenopausal women with breast cancer. An Eastern Cooperative Oncology Group Phase III study. J Clin Oncol 8:599-607, 1990.
162. Levine MM, Gent M, Hyrniuk WM, et al A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 8:1217-1225, 1990.
163. Rivkin SE, Gree S, Metch B, et al: One versus 2 years of CMFVP adjuvant chemotherapy in axilary node-positive and estrogen receptor-negative patients: A Southwest Oncology Group study. J Clin Oncol 11:1710-1716, 1993.
164. Tormey DC, Weinberg VE, Holland JF, et al A randomized trial of five- and three-drug chemotherapy and chemoimmunotherapy in women with operable node-positive breast cancer. J Clin Oncol 1:138, 1983.
165. Wood WC, Weiss RB, Tormey DC, et al: A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB Study. World J Surg 9:114, 1985.
166. Buzdar AU, Blumenshein OR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide, with or without irradiation in operable breast cancer: A prospective randomized trial. Cancer 53:384, 1984.
167. Muss HB, Cooper MR, Brockschmidt JK, et al: A randomized trial of chemotherapy (L Pam vs CMF) and irradiation for node-positive breast cancer: Eleven-year follow-up of a Piedmont Oncology Association trial. Breast Cancer Res Treat 19:77-84, 1991.
168. Buzdar A, Smith T, Blumenschein G, et al: Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC) for stage II or III breast cancer. Five-year results, in Salmon SE and Jones SE (eds): Adjuvant Therapy for Cancer, pp 419-426 New York, Grune & Stratton. 1981.
169. Blomqvist C, Tiusanen K, Elomaa I, et al: The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicinftorafur) and tamoxifen in stage II breast cancer: Long-term follow-up results of a randomized trial. Br J Cancer E16:1171-1176, 1992.